| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
RF Technologies is a leading provider of safety and security solutions for the healthcare, hospitality, and education markets, leveraging radio frequency identification (RFID) and PinPoint® real-time locating system (RTLS) technologies.
Global Health Products Inc is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. The pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. The team is complemented by world-class medical advisors. Our products have been organically conceived, researched and developed by the Company and all manufacturing activities are conducted to ensure compliance with the U.S. Food and Drug Administration (FDA) per the requirements of 21 CFR 820, as well as ISO 13485. Femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the U.S. Food and Drug Administration (FDA), European Union, Canada, and Japan with other select countries in process. Making a difference in the lives of women one product at a time is a great privilege and serves to drive the Company`s mission.
Holistic Industries is dedicated to elevating the future of cannabis through outstanding products, innovative processes, expert education and value for our patients and partners.